ClinicalTrials.Veeva

Menu
C

Clinical Research of Osceola | Kissimmee, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SAR441566
RO7790121
Ustekinumab
BI 3032950
Vedolizumab
Adalimumab
LY4268989
RO7837195
MORF-057
Mirikizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 8 total trials

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ)...

Enrolling
Crohn's Disease
Drug: Vedolizumab
Drug: Adalimumab
Locations recently updated

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Enrolling
Moderately to Severely Active Ulcerative Colitis
Drug: Afimkibart
Drug: Placebo

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance...

Enrolling
Moderately to Severely Active Crohns Disease
Drug: Placebo
Drug: Afimkibart
Locations recently updated

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerativ...

Enrolling
Ulcerative Colitis
Drug: RO7837195 Matched Placebo
Drug: RO7837195

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety o...

Enrolling
Crohn's Disease
Drug: SAR441566
Drug: SAR441566 matching Placebo

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety o...

Enrolling
Colitis Ulcerative
Drug: SAR441566 matching Placebo
Drug: SAR441566

Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment w...

Enrolling
Ulcerative Colitis
Drug: BI 3032950 intravenous (Part A)
Drug: BI 3032950 subcutaneous (Part B)

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in a...

Begins enrollment in 1 month
Ulcerative Colitis
Drug: LY4268989
Drug: Mirikizumab

Trial sponsors

Roche logo
Sanofi logo
Boehringer Ingelheim logo
Genentech logo
Lilly logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems